Improvement in pain and bowel function in female irritable bowel patients with alosetron, a 5-HT3 receptor antagonist

Alimentary Pharmacology and Therapeutics

Volumn 13, Issue 9, 1999, Pages 1149-1159

  Camilleri, M ^a   Mayer, E A ^b   Drossman, D A ^c   Heath, A ^d   Dukes, G E ^d   McSorley, D ^d   Kong, S ^d   Mangel, A W ^d   Northcutt, A R ^d  

^a MAYO CLINIC   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^d GLAXOSMITHKLINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALOSETRON; SEROTONIN 3 ANTAGONIST;

ADULT; ARTICLE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOUBLE BLIND PROCEDURE; FECES; FEMALE; HUMAN; INTESTINE FUNCTION; IRRITABLE COLON; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SEX DIFFERENCE;

ABDOMINAL PAIN; ADULT; CANADA; CARBOLINES; COLONIC DISEASES, FUNCTIONAL; DIARRHEA; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; GERMANY; GREAT BRITAIN; HUMANS; MALE; MIDDLE AGED; NETHERLANDS; SEROTONIN ANTAGONISTS; SEX FACTORS; TREATMENT OUTCOME; UNITED STATES;

EID: 0032848856     PISSN: 02692813     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2036.1999.00610.x     Document Type: Article

References (38)

1. Everhart JE, Renault PF. Irritable bowel syndrome in office-based practice in the United States. Gastroenterology 1991; 100: 998-1005.
2. Camilleri M, Choi M-G. Irritable bowel syndrome. Aliment Pharmacol Ther 1997; 11: 315.
3. Mayer EA, Gebhart GF. Basic and clinical aspects of visceral hyperalgesia. Gastroenterology 1994; 107: 271-93.
4. Drossman DA, Camilleri M, Whitehead WE. Irritable bowel syndrome: a technical review for practice guideline development. Gastroenterology 1997; 112: 2120-37.
5. Zarling EJ, Bernsen MB. The effect of gender on the rates of hospitalization for gastrointestinal illnesses. Am J Gastroenterol 1997; 92: 621-3.
6. Smith RC, Greenbaum DS, Vancouver JB, et al. Gender differences in Manning criteria in the irritable bowel syndrome. Gastroenterology 1991; 100: 591-5.
7. Thompson WG. Gender differences in irritable bowel syndrome. Eur J Gastroenterol Hepatol 1997; 9: 299-302.
8. Silverman DHS, Munakata JA, Mandelkem MA, Hoh CK, Mayer EA. Comparing regional cerebral activity associated with visceral stimuli in male and female patients. J Nucl Med 1997; 38: 273P.
9. Hinds JP, Stoney B, Wald A. Does gender or the menstrual cycle affect colonic transit? Am J Gastroenterol 1989; 84: 123-6.
10. Degen LP, Phillips SF. Variability of gastrointestinal transit in healthy women and men. Gut 1996; 39: 299-305.
11. Meier R, Beglinger C, Dederding JP, et al. Influence of age, gender, hormonal status and smoking habits on colonic transit time. Neurogastroenterol Motility 1995; 7: 235-8.
12. Ritchie J. Pain from distention of the pelvic colon by inflating a balloon in the irritable colon syndrome. Gut 1973; 14: 125-32.
13. Whitehead WE, Holtkotter B, Enck P, et al. Tolerance for rectosigmoid distention in irritable bowel syndrome. Gastroenterology 1990; 98: 1187-92.
14. Bueno L, Fioramonti J, Delvaux M, Frexinos J. Mediators and pharmacology of visceral sensitivity: from basic to clinical investigations. Gastroenterology 1997; 112: 1714-43.
15. Mertz H, Naliboff B, Munakata J, Niazi N, Mayer EA. Altered rectal perception is a biological marker of patients with irritable bowel syndrome. Gastroenterology 1995; 109: 40-52.
16. Moss HE, Sanger GJ. The effects of granisetron, ICS 205-930 and ondansetron on the visceral pain reflex induced by duodenal distension. Br J Pharmacol 1990; 100: 497-501.
17. Scott CM, Grundy D, Boissonade F, Bountra C. Alosetron inhibits the colorectal distention-evoked depressor response and spinal c-fos expression in the anesthetized rat. Gastroenterology 1997; 112: A822(Abstract).
18. Gore S. Gilmore IT, Haigh CG, Brownless SM, Stockdale H, Morris AL. Colonic transit in man is slowed by ondansetron (GR 38032F), a selective 5-hydroxytryptamine receptor (type 3) antagonist. Aliment Pharmacol Ther 1990; 4: 139-44.
19. Talley NJ, Phillips SF, Haddad A, et al. GR 38032F (ondansetron), a selective 5HT3 receptor antagonist. slows colonic transit in healthy man. Dig Dis Sci 1990; 5: 477-80.
20. Zighelboim J, Talley NJ, Phillips SF, Harmsen WS, Zinsmeister AR. Visceral perception in Irritable bowel syndrome. Rectal and gastric responses to distension and serotonin type 3 antagonism. Dig Dis Sci 1995; 40: 819-27.
21. Steadman CJ, Talley NJ, Phillips SF, Zinsmeister AR. Selective 5-hydroxytryptamine receptor antagonism with ondansetron as treatment for diarrhea-predominant irritable bowel syndrome: a pilot study. Mayo Clinic Proc 1992; 67; 732-8.
22. Maxton DG, Morris J, Whorwell PJ. Selective 5-hydroxytryptamine antagonism: a role in irritable bowel syndrome and functional dyspepsia? Aliment Pharmacol Ther 1996; 10: 595-9.
23. Goldberg PA, Kamm MA, Setti-Carraro P, van der Slip JRM, Roth C. Modification of visceral sensitivity and pain in irritable bowel syndrome by 5HT3 antagonism (ondansetron). Digestion 1996; 57: 748-83.
24. von der Ohe MR, Hanson RB, Camilleri M. Serotonergic mediation of postprandial colonic tonic and phasic responses in humans. Gut 1994; 35: 536-41.
25. Prior A, Read NW, Reduction of rectal sensitivity and post-prandial motility by granisetron, a 5HT3 receptor antagonist, in patients with irritable bowel syndrome. Aliment Pharmacol Ther 1993; 7: 175-80.
26. Bardhan K, Bodemar G. Geldef H, Schultz E, Snell C, Darekar B. A double-blind placebo-controlled study to evaluate the efficacy of alosetron in the treatment of irritable bowel syndrome. Gastroenterology 1996; 110: A630(Abstract).
27. Forster JM, Houghton LA, Whorwell PJ. Alosetron slows colonic transit in patients with irritable bowel syndrome. Gastroenterology 1997; 112: A732(Abstract).
28. Thompson WG, Creed F, Drossman DA, Heaton KW, Mazzacca G. Functional bowel disorders and functional abdominal pain. Gastroenterol Intl 1992; 5: 75-91.
29. Harding JP, Hamm LR, Ehsanullah RSB. et al. Use of a novel electronic data collection system in multicenter studies of irritable bowel syndrome. Aliment Pharmacol Ther 1997; 11: 1073-6.
30. Mangel AW, Hahn BA, Heath AT, et al. Adequate relief as an endpoint in clinical trials in irritable bowel syndrome, J Int Med Res 1998; 26: 76-81.
31. Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of discuses. J Natl Cancer Inst 1959; 22: 719-48.
32. Van Elteren PH. On the combination of Independent two sample tests of Wilcoxon. Bull Intl Stat Inst 1960; 37: 351-61.
33. Kilpatrick GJ, Junes BJ, Tyers MB. Identification and distribution of 5-HT3 receptors in rut brain using radioligand binding. Nature 1987; 330: 746-8.
34. Kilpatrick GJ, Jones BJ, Tyers MB. Binding of the 5-HT3 ligand, (3H). GR65630, to rat area postrema, vagus nerve and brains of several species. Eur J Pharmacol 1989; 159: 157-64.
35. Derkach V, Suprenant A, North RA. 5-HT3 receptors are membrane ion channels. Nature 1989; 339: 706-9.
36. 4 receptors in ascending and descending reflexes to the circular muscle of guinea-pig small intestine. Br J Pharmacol 1994; 112: 1095-100.
37. Neya T, Mizutani M, Yamasato T. Role of 5-HT3 receptors in peristaltic reflex elicited by stroking the mucosa in the canine jejunum. J Physiol 1993; 471: 159-73.
38. Mochiki E, Satoh M, Tamura T, et al. Exogenous motilin stimulates endogenous release of motilin through cholinergic muscarinic pathways in the dog. Gastroenterology 1996; 111: 1456-64.